|
1
|
Hany M, Rehman B, Rizvi A and Chapman J:
Schizophrenia. StatPearls. StatPearls Publishing; Treasure Island,
FL: 2024
|
|
2
|
Jauhar S, Johnstone M and McKenna PJ:
Schizophrenia. Lancet. 399:473–486. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keshavan MS, Collin G, Guimond S, Kelly S,
Prasad KM and Lizano P: Neuroimaging in schizophrenia. Neuroimaging
Clin N Am. 30:73–83. 2020. View Article : Google Scholar :
|
|
4
|
DeLisi LE, Szulc KU, Bertisch HC, Majcher
M and Brown K: Understanding structural brain changes in
schizophrenia. Dialogues Clin Neurosci. 8:71–78. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldwaser EL, Swanson RL II, Arroyo EJ,
Venkataraman V, Kosciuk MC, Nagele RG, Hong LE and Acharya NK: A
preliminary report: The hippocampus and surrounding temporal cortex
of patients with schizophrenia have impaired blood-brain barrier.
Front Hum Neurosci. 16:8369802022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goldwaser EL, Wang DJJ, Adhikari BM,
Chiappelli J, Shao X, Yu J, Lu T, Chen S, Marshall W, Yuen A, et
al: Evidence of neurovascular water exchange and endothelial
vascular dysfunction in schizophrenia: An exploratory study.
Schizophr Bull. 49:1325–1335. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pardridge WM: Drug transport across the
blood-brain barrier. J Cereb Blood Flow Metab. 32:1959–1972. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daneman R and Prat A: The blood-brain
barrier. Cold Spring Harb Perspect Biol. 7:a0204122015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Knox EG, Aburto MR, Clarke G, Cryan JF and
O'Driscoll CM: The blood-brain barrier in aging and
neurodegeneration. Mol Psychiatry. 27:2659–2673. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Najjar S, Pahlajani S, De Sanctis V, Stern
JNH, Najjar A and Chong D: Neurovascular unit dysfunction and
blood-brain barrier hyperpermeability contribute to schizophrenia
neurobiology: A theoretical integration of clinical and
experimental evidence. Front Psychiatry. 8:832017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Puvogel S, Palma V and Sommer IEC: Brain
vasculature disturbance in schizophrenia. Curr Opin Psychiatry.
35:146–156. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Greene C, Kealy J, Humphries MM, Gong Y,
Hou J, Hudson N, Cassidy LM, Martiniano R, Shashi V, Hooper SR, et
al: Dose-dependent expression of claudin-5 is a modifying factor in
schizophrenia. Mol Psychiatry. 23:2156–2166. 2018. View Article : Google Scholar :
|
|
13
|
Greene C, Hanley N and Campbell M:
Blood-brain barrier associated tight junction disruption is a
hallmark feature of major psychiatric disorders. Transl Psychiatry.
10:3732020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moussiopoulou J, Yakimov V, Roell L,
Rauchmann BS, Toth H, Melcher J, Jäger I, Lutz I, Kallweit MS,
Papazov B, et al: Higher blood-brain barrier leakage in
schizophrenia-spectrum disorders: A comparative dynamic
contrast-enhanced magnetic resonance imaging study with healthy
controls. Brain Behav Immun. 128:256–265. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Murray AJ, Rogers JC, Katshu MZUH, Liddle
PF and Upthegrove R: Oxidative stress and the pathophysiology and
symptom profile of schizophrenia spectrum disorders. Front
Psychiatry. 12:7034522021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su G, Chen Y, Li X and Shao JW: Virus
versus host: Influenza A virus circumvents the immune responses.
Front Microbiol. 15:13945102024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giordano GM, Bucci P, Mucci A, Pezzella P
and Galderisi S: Gender differences in clinical and psychosocial
features among persons with schizophrenia: A mini review. Front
Psychiatry. 12:7891792021. View Article : Google Scholar
|
|
18
|
Maurus I, Wagner S, Campana M, Roell L,
Strauss J, Fernando P, Muenz S, Eichhorn P, Schmitt A, Karch S, et
al: The relationship between blood-brain barrier dysfunction and
neurocognitive impairments in first-episode psychosis: Findings
from a retrospective chart analysis. BJPsych Open. 9:e602023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCutcheon RA, Reis Marques T and Howes
OD: schizophrenia-an overview. JAMA Psychiatry. 77:201–210. 2020.
View Article : Google Scholar
|
|
20
|
Kay SR, Fiszbein A and Opler LA: The
positive and negative syndrome scale (PANSS) for schizophrenia.
Schizophr Bull. 13:261–276. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim K, Peh OH, Yang Z, Rekhi G, Rapisarda
A, See YM, Rashid NAA, Ang MS, Lee SA, Sim K, et al: Large-scale
evaluation of the positive and negative syndrome scale (PANSS)
symptom architecture in schizophrenia. Asian J Psychiatr.
62:1027322021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karlsgodt KH, Sun D and Cannon TD:
Structural and functional brain abnormalities in schizophrenia.
Curr Dir Psychol Sci. 19:226–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dabiri M, Dehghani Firouzabadi F, Yang K,
Barker PB, Lee RR and Yousem DM: Neuroimaging in schizophrenia: A
review article. Front Neurosci. 16:10428142022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tønnesen S, Kaufmann T, Doan NT, Alnæs D,
Córdova-Palomera A, Meer DV, Rokicki J, Moberget T, Gurholt TP,
Haukvik UK, et al: White matter aberrations and age-related
trajectories in patients with schizophrenia and bipolar disorder
revealed by diffusion tensor imaging. Sci Rep. 8:141292018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kubicki M, McCarley R, Westin CF, Park HJ,
Maier S, Kikinis R, Jolesz FA and Shenton ME: A review of diffusion
tensor imaging studies in schizophrenia. J Psychiatr Res. 41:15–30.
2007. View Article : Google Scholar
|
|
26
|
Trifu SC, Kohn B, Vlasie A and Patrichi
BE: Genetics of schizophrenia (review). Exp Ther Med. 20:3462–3468.
2020.PubMed/NCBI
|
|
27
|
V'Kovski P, Kratzel A, Steiner S, Stalder
H and Thiel V: Coronavirus biology and replication: Implications
for SARS-CoV-2. Nat Rev Microbiol. 19:155–170. 2021. View Article : Google Scholar
|
|
28
|
Georgiades A, Almuqrin A, Rubinic P,
Mouhitzadeh K, Tognin S and Mechelli A: Psychosocial stress,
interpersonal sensitivity, and social withdrawal in clinical high
risk for psychosis: A systematic review. Schizophrenia (Heidelb).
9:382023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nisha Aji K, Lalang N, Ramos-Jiménez C,
Rahimian R, Mechawar N, Turecki G, Chartrand D, Boileau I, Meyer
JH, Rusjan PM and Mizrahi R: Evidence of altered monoamine oxidase
B, an astroglia marker, in early psychosis and high-risk state. Mol
Psychiatry. 30:2049–2058. 2025. View Article : Google Scholar
|
|
30
|
Schmitt A, Falkai P and Papiol S:
Neurodevelopmental disturbances in schizophrenia: Evidence from
genetic and environmental factors. J Neural Transm (Vienna).
130:195–205. 2023. View Article : Google Scholar
|
|
31
|
Kotsiri I, Resta P, Spyrantis A,
Panotopoulos C, Chaniotis D, Beloukas A and Magiorkinis E: Viral
infections and schizophrenia: A comprehensive review. Viruses.
15:13452023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Selemon LD and Zecevic N: Schizophrenia: A
tale of two critical periods for prefrontal cortical development.
Transl Psychiatry. 5:e6232015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sekar A, Bialas AR, de Rivera H, Davis A,
Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V,
et al: Schizophrenia risk from complex variation of complement
component 4. Nature. 530:177–183. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Uliana DL, Zhu X, Gomes FV and Grace AA:
Using animal models for the studies of schizophrenia and
depression: The value of translational models for treatment and
prevention. Front Behav Neurosci. 16:9353202022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mei L and Xiong WC: Neuregulin 1 in neural
development, synaptic plasticity and schizophrenia. Nat Rev
Neurosci. 9:437–452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Soares DC, Carlyle BC, Bradshaw NJ and
Porteous DJ: DISC1: Structure, function, and therapeutic potential
for major mental illness. ACS Chem Neurosci. 2:609–632. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen L, Xu J, Zhu L, Xu P, Chang L, Han Y
and Wu Q: Disrupted in schizophrenia 1 reverse ectopic migration of
neural precursors in mouse hilus after pilocarpine-induced status
epilepticus. Mol Neurobiol. 60:6689–6703. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Breitmeyer R, Vogel S, Heider J, Hartmann
SM, Wüst R, Keller AL, Binner A, Fitzgerald JC, Fallgatter AJ and
Volkmer H: Regulation of synaptic connectivity in schizophrenia
spectrum by mutual neuron-microglia interaction. Commun Biol.
6:4722023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McGrath J, Saari K, Hakko H, Jokelainen J,
Jones P, Järvelin MR, Chant D and Isohanni M: Vitamin D
supplementation during the first year of life and risk of
schizophrenia: A Finnish birth cohort study. Schizophr Res.
67:237–245. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Duan L, Li S, Chen D, Shi Y, Zhou X and
Feng Y: Causality between autoimmune diseases and schizophrenia: A
bidirectional Mendelian randomization study. BMC Psychiatry.
24:8172024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bondrescu M, Dehelean L, Farcas SS, Papava
I, Nicoras V, Podaru CA, Sava M, Bilavu ES, Putnoky S and Andreescu
NI: Cognitive impairments related to COMT and neuregulin 1
phenotypes as transdiagnostic markers in schizophrenia spectrum
patients. J Clin Med. 13:64052024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bergen SE, Fanous AH, Walsh D, O'Neill FA
and Kendler KS: Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and
modification of psychotic disorder features. Schizophr Res.
109:94–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang AC and Tsai SJ: New targets for
schizophrenia treatment beyond the dopamine hypothesis. Int J Mol
Sci. 18:16892017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Luvsannyam E, Jain MS, Pormento MKL,
Siddiqui H, Balagtas ARA, Emuze BO and Poprawski T: Neurobiology of
schizophrenia: A comprehensive review. Cureus.
14:e239592022.PubMed/NCBI
|
|
45
|
Wu Q, Huang J and Wu R: Drugs based on
NMDAR hypofunction hypothesis in schizophrenia. Front Neurosci.
15:6410472021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
McCutcheon RA, Krystal JH and Howes OD:
Dopamine and glutamate in schizophrenia: Biology, symptoms and
treatment. World Psychiatry. 19:15–33. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kruse AO and Bustillo JR: Glutamatergic
dysfunction in schizophrenia. Transl Psychiatry. 12:5002022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jain R, Chepke C, Davis LL, McIntyre RS
and Raskind MA: Dysregulation of noradrenergic activity: Its role
in conceptualizing and treating major depressive disorder,
schizophrenia, agitation in Alzheimer's disease, and posttraumatic
stress disorder. J Clin Psychiatry. 85:plunaro2417ah2024.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Murphy CE, Walker AK and Weickert CS:
Neuroinflammation in schizophrenia: The role of nuclear factor
kappa B. Transl Psychiatry. 11:5282021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hughes H, Brady LJ and Schoonover KE:
GABAergic dysfunction in postmortem dorsolateral prefrontal cortex:
Implications for cognitive deficits in schizophrenia and affective
disorders. Front Cell Neurosci. 18:14408342024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Müller N, Weidinger E, Leitner B and
Schwarz MJ: The role of inflammation in schizophrenia. Front
Neurosci. 9:3722015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Borovcanin MM, Jovanovic I, Radosavljevic
G, Pantic J, Minic Janicijevic S, Arsenijevic N and Lukic ML:
Interleukin-6 in schizophrenia-is there a therapeutic relevance?
Front Psychiatry. 8:2212017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Brown AS: Exposure to prenatal infection
and risk of schizophrenia. Front Psychiatry. 2:632011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jenkins TA: Perinatal complications and
schizophrenia: Involvement of the immune system. Front Neurosci.
7:1102013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chandra J: The potential role of the p75
receptor in schizophrenia: Neuroimmunomodulation and making life or
death decisions. Brain Behav Immun Health. 38:1007962024.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hu W, MacDonald ML, Elswick DE and Sweet
RA: The glutamate hypothesis of schizophrenia: Evidence from human
brain tissue studies. Ann N Y Acad Sci. 1338:38–57. 2015.
View Article : Google Scholar :
|
|
57
|
Chen L, Zhu L, Xu J, Xu P, Han Y, Chang L
and Wu Q: Disrupted in schizophrenia 1 regulates ectopic
neurogenesis in the mouse hilus after pilocarpine-induced status
epilepticus. Neuroscience. 494:69–81. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Winship IR, Dursun SM, Baker GB, Balista
PA, Kandratavicius L, Maia-de-Oliveira JP, Hallak J and Howland JG:
An overview of animal models related to schizophrenia. Can J
Psychiatry. 64:5–17. 2019. View Article : Google Scholar :
|
|
59
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Deserno L, Schlagenhauf F and Heinz A:
Striatal dopamine, reward, and decision making in schizophrenia.
Dialogues Clin Neurosci. 18:77–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Eisenberg DP, Yankowitz L, Ianni AM,
Rubinstein DY, Kohn PD, Hegarty CE, Gregory MD, Apud JA and Berman
KF: Presynaptic dopamine synthesis capacity in schizophrenia and
striatal blood flow change during antipsychotic treatment and
medication-free conditions. Neuropsychopharmacology. 42:2232–2241.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bulumulla C, Walpita D, Iyer N, Eddison M,
Patel R, Alcor D, Ackerman D and Beyene AG: Synaptic
specializations at dopamine release sites orchestrate efficient and
precise neuromodulatory signaling. bioRxiv: 2024.09.16.613338.
2024.
|
|
63
|
Jahangir M, Zhou JS, Lang B and Wang XP:
GABAergic system dysfunction and challenges in schizophrenia
research. Front Cell Dev Biol. 9:6638542021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cohen SM, Tsien RW, Goff DC and Halassa
MM: The impact of NMDA receptor hypofunction on GABAergic neurons
in the pathophysiology of schizophrenia. Schizophr Res. 167:98–107.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Khandaker GM, Cousins L, Deakin J, Lennox
BR, Yolken R and Jones PB: Inflammation and immunity in
schizophrenia: Implications for pathophysiology and treatment.
Lancet Psychiatry. 2:258–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Müller N and Schwarz MJ: Immune system and
Schizophrenia. Curr Immunol Rev. 6:213–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Vallée A: Neuroinflammation in
schizophrenia: The key role of the WNT/β-catenin pathway. Int J Mol
Sci. 23:28102022. View Article : Google Scholar
|
|
68
|
Ebrahimi M, Teymouri K, Chen CC, Mohiuddin
AG, Pouget JG, Goncalves VF, Tiwari AK, Zai CC and Kennedy JL:
Association study of the complement component C4 gene and suicide
risk in schizophrenia. Schizophrenia (Heidelb). 10:142024.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mokhtari R and Lachman HM: The major
histocompatibility complex (MHC) in schizophrenia: A review. J Clin
Cell Immunol. 7:4792016. View Article : Google Scholar
|
|
70
|
Jeppesen R, Orlovska-Waast S, Sørensen NV,
Christensen RHB and Benros ME: Cerebrospinal fluid and blood
biomarkers of neuroinflammation and blood-brain barrier in
psychotic disorders and individually matched healthy controls.
Schizophr Bull. 48:1206–1216. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Orlovska-Waast S, Köhler-Forsberg O, Brix
SW, Nordentoft M, Kondziella D, Krogh J and Benros ME:
Cerebrospinal fluid markers of inflammation and infections in
schizophrenia and affective disorders: A systematic review and
meta-analysis. Mol Psychiatry. 24:869–887. 2019. View Article : Google Scholar :
|
|
72
|
Chaves C, Dursun SM, Tusconi M and Hallak
JEC: Neuroinflammation and schizophrenia-is there a link? Front
Psychiatry. 15:13569752024. View Article : Google Scholar
|
|
73
|
Garver DL, Tamas RL and Holcomb JA:
Elevated interleukin-6 in the cerebrospinal fluid of a previously
delineated schizophrenia subtype. Neuropsychopharmacology.
28:1515–1520. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhilyaeva TV, Rukavishnikov GV, Manakova
EA and Mazo GE: Serum interleukin-6 in schizophrenia: Associations
with clinical and sociodemographic characteristics. Consort
Psychiatr. 4:5–16. 2023.
|
|
75
|
Fond G, Lançon C, Korchia T, Auquier P and
Boyer L: The role of inflammation in the treatment of
schizophrenia. Front Psychiatry. 11:1602020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Miller BJ, Buckley P, Seabolt W, Mellor A
and Kirkpatrick B: Meta-analysis of cytokine alterations in
schizophrenia: Clinical status and antipsychotic effects. Biol
Psychiatry. 70:663–671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li Y, Li YJ and Zhu ZQ: To re-examine the
intersection of microglial activation and neuroinflammation in
neurodegenerative diseases from the perspective of pyroptosis.
Front Aging Neurosci. 15:12842142023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Salim S: Oxidative stress and the central
nervous system. J Pharmacol Exp Ther. 360:201–205. 2017. View Article : Google Scholar :
|
|
79
|
Choudhury Z and Lennox B: Maternal immune
activation and schizophrenia-evidence for an immune priming
disorder. Front Psychiatry. 12:5857422021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Siafis S, Wu H, Wang D, Burschinski A,
Nomura N, Takeuchi H, Schneider-Thoma J, Davis JM and Leucht S:
Antipsychotic dose, dopamine D2 receptor occupancy and
extrapyramidal side-effects: A systematic review and dose-response
meta-analysis. Mol Psychiatry. 28:3267–3277. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kapur S, Zipursky R, Jones C, Remington G
and Houle S: Relationship between dopamine D(2) occupancy, clinical
response, and side effects: A double-blind PET study of
first-episode schizophrenia. Am J Psychiatry. 157:514–520. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Grinchii D and Dremencov E: Mechanism of
action of atypical antipsychotic drugs in mood disorders. Int J Mol
Sci. 21:95322020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Richtand NM, Welge JA, Logue AD, Keck PE
Jr, Strakowski SM and McNamara RK: Dopamine and serotonin receptor
binding and antipsychotic efficacy. Neuropsychopharmacology.
32:1715–1726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Mørup MF, Kymes SM and Oudin Åström D:
PLoS One. 15:e02341212020. View Article : Google Scholar
|
|
85
|
Potkin SG, Kane JM, Correll CU,
Lindenmayer JP, Agid O, Marder SR, Olfson M and Howes OD: The
neurobiology of treatment-resistant schizophrenia: Paths to
antipsychotic resistance and a roadmap for future research. NPJ
Schizophr. 6:12020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Müller N, Strassnig M, Schwarz MJ,
Ulmschneider M and Riedel M: COX-2 inhibitors as adjunctive therapy
in schizophrenia. Expert Opin Investig Drugs. 13:1033–1044. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Deakin B, Suckling J, Barnes TRE, Byrne K,
Chaudhry IB, Dazzan P, Drake RJ, Giordano A, Husain N, Jones PB, et
al: The benefit of minocycline on negative symptoms of
schizophrenia in patients with recent-onset psychosis (BeneMin): A
randomised, double-blind, placebo-controlled trial. Lancet
Psychiatry. 5:885–894. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Tenório MCDS, Graciliano NG, Moura FA,
Oliveira ACM and Goulart MOF: N-acetylcysteine (NAC): Impacts on
human health. Antioxidants (Basel). 10:9672021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ghaderi A, Bussu A, Tsang C and Jafarnejad
S: Effect of N-acetylcysteine on positive and negative syndrome
scale associated with schizophrenia: A meta-analysis. Rev Clin Med.
7:134–144. 2020.
|
|
90
|
Titulaer J, Radhe O, Danielsson K, Dutheil
S, Marcus MM, Jardemark K, Svensson TH, Snyder GL, Ericson M, Davis
RE and Konradsson-Geuken Å: Lumateperone-mediated effects on
prefrontal glutamatergic receptor-mediated neurotransmission: A
dopamine D1 receptor dependent mechanism. Eur
Neuropsychopharmacol. 62:22–35. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Edinoff A, Wu N, deBoisblanc C, Feltner
CO, Norder M, Tzoneva V, Kaye AM, Cornett EM, Kaye AD, Viswanath O
and Urits I: Lumateperone for the treatment of schizophrenia.
Psychopharmacol Bull. 50:32–59. 2020.PubMed/NCBI
|
|
92
|
Correll CU, Davis RE, Weingart M, Saillard
J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S and
Vanover KE: Efficacy and safety of lumateperone for treatment of
schizophrenia: A randomized clinical trial. JAMA Psychiatry.
77:3492020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Krasavin M, Peshkov AA, Lukin A, Komarova
K, Vinogradova L, Smirnova D, Kanov EV, Kuvarzin SR, Murtazina RZ,
Efimova EV, et al: Discovery and in vivo efficacy of trace
amine-associated receptor 1 (TAAR1) agonist
4-(2-Aminoethyl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide
hydrochloride (AP163) for the treatment of psychotic disorders. Int
J Mol Sci. 23:115792022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Achtyes ED, Hopkins SC, Dedic N, Dworak H,
Zeni C and Koblan K: Ulotaront: Review of preliminary evidence for
the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur
Arch Psychiatry Clin Neurosci. 273:1543–1556. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Alajangi HK, Kaur M, Sharma A, Rana S,
Thakur S, Chatterjee M, Singla N, Jaiswal PK, Singh G and Barnwal
RP: Blood-brain barrier: Emerging trends on transport models and
new-age strategies for therapeutics intervention against
neurological disorders. Mol Brain. 15:492022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Greene C, Hanley N and Campbell M:
Claudin-5: Gatekeeper of neurological function. Fluids Barriers
CNS. 16:32019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zapata-Acevedo JF, García-Pérez V,
Cabezas-Pérez R, Losada-Barragán M, Vargas-Sánchez K and
González-Reyes RE: Laminin as a biomarker of blood-brain barrier
disruption under neuroinflammation: A systematic review. Int J Mol
Sci. 23:67882022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Baeten KM and Akassoglou K: Extracellular
matrix and matrix receptors in blood-brain barrier formation and
stroke. Dev Neurobiol. 71:1018–1039. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Serlin Y, Shelef I, Knyazer B and Friedman
A: Anatomy and physiology of the blood-brain barrier. Semin Cell
Dev Biol. 38:2–6. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Kadry H, Noorani B and Cucullo L: A
blood-brain barrier overview on structure, function, impairment,
and biomarkers of integrity. Fluids Barriers CNS. 17:692020.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Löscher W and Potschka H: Blood-brain
barrier active efflux transporters: ATP-binding cassette gene
family. NeuroRx. 2:86–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang F, Zhang J, Wang X, Han M, Fei Y and
Wang J: Blood-brain barrier disruption in schizophrenia: Insights,
mechanisms, and future directions. Int J Mol Sci. 26:8732025.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Oviedo-Salcedo T, Wagner E, Campana M,
Gagsteiger A, Strube W, Eichhorn P, Louiset ML, Luykx J, de Witte
LD, Kahn RS, et al: Cerebrospinal fluid abnormalities in first- and
multi-episode schizophrenia-spectrum disorders: Impact of clinical
and demographical variables. Transl Psychiatry. 11:6212021.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Koh SXT and Lee JKW: S100B as a marker for
brain damage and blood-brain barrier disruption following exercise.
Sports Med. 44:369–385. 2014. View Article : Google Scholar
|
|
105
|
Rempe RG, Hartz AMS and Bauer B: Matrix
metalloproteinases in the brain and blood-brain barrier: Versatile
breakers and makers. J Cereb Blood Flow Metab. 36:1481–1507. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Turner RJ and Sharp FR: Implications of
MMP9 for blood brain barrier disruption and hemorrhagic
transformation following ischemic stroke. Front Cell Neurosci.
10:562016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Omidinia E, Mashayekhi Mazar F, Shahamati
P, Kianmehr A and Shahbaz Mohammadi H: Polymorphism of the CLDN5
gene and schizophrenia in an iranian population. Iran J Public
Health. 43:79–83. 2014.PubMed/NCBI
|
|
108
|
Usta A, Kılıç F, Demirdaş A, Işık Ü, Doğuç
DK and Bozkurt M: Serum zonulin and claudin-5 levels in patients
with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 271:767–773.
2021. View Article : Google Scholar
|
|
109
|
Zengil S and Laloğlu E: Evaluation of
serum zonulin and occludin levels in bipolar disorder. Psychiatry
Investig. 20:382–389. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Fasano A: All disease begins in the
(leaky) gut: Role of zonulin-mediated gut permeability in the
pathogenesis of some chronic inflammatory diseases. F1000Res.
9:F1000 Faculty Rev-69. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Puvogel S, Alsema A, Kracht L, Webster MJ,
Weickert CS, Sommer IEC and Eggen BJL: Single-nucleus RNA
sequencing of midbrain blood-brain barrier cells in schizophrenia
reveals subtle transcriptional changes with overall preservation of
cellular proportions and phenotypes. Mol Psychiatry. 27:4731–4740.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Kornhuber J, Wiltfang J, Riederer P and
Bleich S: Neuroleptic drugs in the human brain: Clinical impact of
persistence and region-specific distribution. Eur Arch Psychiatry
Clin Neurosci. 256:274–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Kalaria RN, Akinyemi R and Ihara M: Stroke
injury, cognitive impairment and vascular dementia. Biochim Biophys
Acta. 1862:915–925. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kanbay M, Ozbek L, Guldan M, Abdel-Rahman
SM, Sisman U, Mallamaci F and Zoccali C: Nutrition, cognition and
chronic kidney disease: A comprehensive review of interactions and
interventions. Eur J Clin Invest. 55:e700452025. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Case M, Stauffer VL, Ascher-Svanum H,
Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J and Kinon BJ:
The heterogeneity of antipsychotic response in the treatment of
schizophrenia. Psychol Med. 41:1291–1300. 2011. View Article : Google Scholar :
|
|
116
|
Kirch DG, Alexander RC, Suddath RL,
Papadopoulos NM, Kaufmann CA, Daniel DG and Wyatt RJ: Blood-CSF
barrier permeability and central nervous system immunoglobulin G in
schizophrenia. J Neural Transm Gen Sect. 89:219–2132. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Rowsthorn E, Pham W, Nazem-Zadeh MR, Law
M, Pase MP and Harding IH: Imaging the neurovascular unit in health
and neurodegeneration: A scoping review of interdependencies
between MRI measures. Fluids Barriers CNS. 20:972023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Cheng Y, Wang T, Zhang T, Yi S, Zhao S, Li
N, Yang Y, Zhang F, Xu L, Shan B, et al: Increased blood-brain
barrier permeability of the thalamus correlated with symptom
severity and brain volume alterations in patients with
schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging.
7:1025–1034. 2022.PubMed/NCBI
|
|
119
|
Chung KJ, Abdelhafez YG, Spencer BA, Jones
T, Tran Q, Nardo L, Chen MS Jr, Sarkar S, Medici V, Lyo V, et al:
Quantitative PET imaging and modeling of molecular blood-brain
barrier permeability. medRxiv [Preprint]: 2024.07.26.24311027.
2024.
|
|
120
|
Crockett AM, Ryan SK, Vásquez AH, Canning
C, Kanyuch N, Kebir H, Ceja G, Gesualdi J, Zackai E,
McDonald-McGinn D, et al: Disruption of the blood-brain barrier in
22q11.2 deletion syndrome. Brain. 144:1351–1360. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Hashimoto Y, Greene C, Munnich A and
Campbell M: The CLDN5 gene at the blood-brain barrier in health and
disease. Fluids Barriers CNS. 20:222023. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Casas BS, Arancibia-Altamirano D,
Acevedo-La Rosa F, Garrido-Jara D, Maksaev V, Pérez-Monje D and
Palma V: It takes two to tango: Widening our understanding of the
onset of schizophrenia from a neuro-angiogenic perspective. Front
Cell Dev Biol. 10:9467062022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Laksitorini MD, Yathindranath V, Xiong W,
Hombach-Klonisch S and Miller DW: Modulation of Wnt/β-catenin
signaling promotes blood-brain barrier phenotype in cultured brain
endothelial cells. Sci Rep. 9:197182019. View Article : Google Scholar
|
|
124
|
Liu X, Low SK, Atkins JR, Wu JQ, Reay WR,
Cairns HM, Green MJ, Schall U, Jablensky A, Mowry B, et al: Wnt
receptor gene FZD1 was associated with schizophrenia in genome-wide
SNP analysis of the Australian schizophrenia research bank cohort.
Aust N Z J Psychiatry. 54:902–908. 2020. View Article : Google Scholar
|
|
125
|
Fusaro A, Zecchin B, Giussani E, Palumbo
E, Agüero-García M, Bachofen C, Bálint Á, Banihashem F, Banyard AC,
Beerens N, et al: High pathogenic avian influenza A(H5) viruses of
clade 2.3.4.4b in Europe-why trends of virus evolution are more
difficult to predict. Virus Evol. 10:veae0272024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yu X, Ji C and Shao A: Neurovascular unit
dysfunction and neurodegenerative disorders. Front Neurosci.
14:3342020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zhao FY, Fu QQ, Spencer SJ, Kennedy GA,
Conduit R, Zhang WJ and Zheng Z: Acupuncture: A promising approach
for comorbid depression and insomnia in perimenopause. Nat Sci
Sleep. 13:1823–1863. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Chen J, Xue K, Yang M, Wang K, Xu Y, Wen
B, Cheng J, Han S and Wei Y: Altered coupling of cerebral blood
flow and functional connectivity strength in first-episode
schizophrenia patients with auditory verbal hallucinations. Front
Neurosci. 16:8210782022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Sukumar N, Sabesan P, Anazodo U and
Palaniyappan L: Neurovascular uncoupling in schizophrenia: A
bimodal meta-analysis of brain perfusion and glucose metabolism.
Front Psychiatry. 11:7542020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Iadecola C: The neurovascular unit coming
of age: A journey through neurovascular coupling in health and
disease. Neuron. 96:17–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Matrisciano F: Functional nutrition as
integrated intervention for in- and outpatient with schizophrenia.
Curr Neuropharmacol. 21:2409–2423. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Shebl N: Neuroinflammation and microglial
activation in schizophrenia: An overview. Handbook of
Neurodegenerative Disorders. Mohamed E: Springer Nature Singapore;
Singapore: pp. 1–16. 2023
|
|
133
|
Stanca S, Rossetti M, Bokulic Panichi L
and Bongioanni P: The cellular dysfunction of the brain-blood
barrier from endothelial cells to astrocytes: The pathway towards
neurotransmitter impairment in schizophrenia. Int J Mol Sci.
25:12502024. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Bitanihirwe BK and Woo TU: Oxidative
stress in schizophrenia: An integrated approach. Neurosci Biobehav
Rev. 35:878–893. 2011. View Article : Google Scholar :
|
|
135
|
Cuenod M, Steullet P, Cabungcal JH, Dwir
D, Khadimallah I, Klauser P, Conus P and Do KQ: Caught in vicious
circles: A perspective on dynamic feed-forward loops driving
oxidative stress in schizophrenia. Mol Psychiatry. 27:1886–1897.
2022. View Article : Google Scholar :
|
|
136
|
Zang X, Chen S, Zhu J, Ma J and Zhai Y:
The emerging role of central and peripheral immune systems in
neurodegenerative diseases. Front Aging Neurosci. 14:8721342022.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Hammer C, Zerche M, Schneider A, Begemann
M, Nave KA and Ehrenreich H: Apolipoprotein E4 carrier status plus
circulating anti-NMDAR1 autoantibodies: Association with
schizoaffective disorder. Mol Psychiatry. 19:1054–1056. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Ladépêche L, Planagumà J, Thakur S, Suárez
I, Hara M, Borbely JS, Sandoval A, Laparra-Cuervo L, Dalmau J and
Lakadamyali M: NMDA receptor autoantibodies in autoimmune
encephalitis cause a subunit-specific nanoscale redistribution of
NMDA receptors. Cell Rep. 23:3759–3768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Hawkins RA, Mans AM, Hibbard LS, Davis DW
and Biebuyck JF: Regional transport of some essential nutrients
across the blood-brain barrier in normal and diseased states. Ann N
Y Acad Sci. 529:40–49. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Srivastav S, Cui X, Varela RB, Kesby JP
and Eyles D: Increasing dopamine synthesis in nigrostriatal
circuits increases phasic dopamine release and alters dorsal
striatal connectivity: Implications for schizophrenia.
Schizophrenia (Heidelb). 9:692023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Pollak TA, Drndarski S, Stone JM, David
AS, McGuire P and Abbott NJ: The blood-brain barrier in psychosis.
Lancet Psychiatry. 5:79–92. 2018. View Article : Google Scholar
|
|
142
|
Fang K, Wen B, Niu L, Wan B and Zhang W:
Higher brain structural heterogeneity in schizophrenia. Front
Psychiatry. 13:10173992022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Gammon D, Cheng C, Volkovinskaia A, Baker
GB and Dursun SM: Clozapine: Why is it so uniquely effective in the
treatment of a range of neuropsychiatric disorders? Biomolecules.
11:10302021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Brown AS: The environment and
susceptibility to schizophrenia. Prog Neurobiol. 93:23–58. 2011.
View Article : Google Scholar
|
|
145
|
Wang YI, Abaci HE and Shuler ML:
Microfluidic blood-brain barrier model provides in vivo-like
barrier properties for drug permeability screening. Biotechnol
Bioeng. 114:184–194. 2017. View Article : Google Scholar
|
|
146
|
Brown TD, Nowak M, Bayles AV,
Prabhakarpandian B, Karande P, Lahann J, Helgeson ME and Mitragotri
S: A microfluidic model of human brain (μHuB) for assessment of
blood brain barrier. Bioeng Transl Med. 4:e101262019. View Article : Google Scholar
|
|
147
|
Kawakita S, Mandal K, Mou L, Mecwan MM,
Zhu Y, Li S, Sharma S, Hernandez AL, Nguyen HT, Maity S, et al:
Organ-On-A-chip models of the blood-brain barrier: Recent advances
and future prospects. Small. 18:e22014012022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Chen X, Liu C, Muok L, Zeng C and Li Y:
Dynamic 3D On-chip BBB model design, development, and applications
in neurological diseases. Cells. 10:31832021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Stankovic I, Notaras M, Wolujewicz P, Lu
T, Lis R, Ross ME and Colak D: Schizophrenia endothelial cells
exhibit higher permeability and altered angiogenesis patterns in
patient-derived organoids. Transl Psychiatry. 14:532024. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Dao L, You Z, Lu L, Xu T, Sarkar AK, Zhu
H, Liu M, Calandrelli R, Yoshida G, Lin P, et al: Modeling
blood-brain barrier formation and cerebral cavernous malformations
in human PSC-derived organoids. Cell Stem Cell. 31:818–833.e11.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Kiparizoska S and Ikuta T: Disrupted
olfactory integration in schizophrenia: Functional connectivity
study. Int J Neuropsychopharmacol. 20:740–746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Moberg PJ, Agrin R, Gur RE, Gur RC,
Turetsky BI and Doty RL: Olfactory dysfunction in schizophrenia: A
qualitative and quantitative review. Neuropsychopharmacology.
21:325–340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Cascella NG, Takaki M, Lin S and Sawa A:
Neurodevelopmental involvement in schizophrenia: The olfactory
epithelium as an alternative model for research. J Neurochem.
102:587–594. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Tung VSK, Mathews F, Boruk M, Suppa G,
Foronjy R, Pato MT, Pato CN, Knowles JA and Evgrafov OV: Cultured
mesenchymal cells from nasal turbinate as a cellular model of the
neurodevelopmental component of schizophrenia etiology. Int J Mol
Sci. 24:153392023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Yang K, Hasegawa Y, Bhattarai JP, Hua J,
Dower M, Etyemez S, Prasad N, Duvall L, Paez A, Smith A, et al:
Inflammation-related pathology in the olfactory epithelium: Its
impact on the olfactory system in psychotic disorders. Mol
Psychiatry. 29:1453–1464. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Deng H, Kahlon RS, Mohite S, Amin PA,
Zunta-Soares G, Colpo GD, Stertz L, Fries GR, Walss-Bass C, Soares
JC and Okusaga OO: Elevated plasma S100B, psychotic symptoms, and
cognition in schizophrenia. Psychiatr Q. 89:53–60. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Langeh U and Singh S: Targeting S100B
protein as a surrogate biomarker and its role in various
neurological disorders. Curr Neuropharmacol. 19:265–277. 2021.
View Article : Google Scholar :
|
|
158
|
Chen L, Sutharsan R, Lee JL, Cruz E,
Asnicar B, Palliyaguru T, Wasielewska JM, Gaudin A, Song J,
Leinenga G and Götz J: Claudin-5 binder enhances focused
ultrasound-mediated opening in an in vitro blood-brain barrier
model. Theranostics. 12:1952–1970. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yuan S, Liu KJ and Qi Z: Occludin
regulation of blood-brain barrier and potential therapeutic target
in ischemic stroke. Brain Circ. 6:152–162. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Dancy C, Heintzelman KE and Katt ME: The
glycocalyx: The importance of sugar coating the blood-brain
barrier. Int J Mol Sci. 25:84042024. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Zorkina Y, Abramova O, Ushakova V,
Morozova A, Zubkov E, Valikhov M, Melnikov P, Majouga A and
Chekhonin V: Nano carrier drug delivery systems for the treatment
of neuropsychiatric disorders: Advantages and limitations.
Molecules. 25:52942020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Hashimoto Y and Campbell M: Tight junction
modulation at the blood-brain barrier: Current and future
perspectives. Biochim Biophys Acta Biomembr. 1862:1832982020.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Zhang T, Wu J, Yao X, Zhang Y, Wang Y, Han
Y, Wu Y, Xu Z, Lan J, Han S, et al: The aldose reductase inhibitor
epalrestat maintains blood-brain barrier integrity by enhancing
endothelial cell function during cerebral ischemia. Mol Neurobiol.
60:3741–3757. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Shi SM, Suh RJ, Shon DJ, Garcia FJ, Buff
JK, Atkins M, Li L, Lu N, Sun B, Luo J, et al: Glycocalyx
dysregulation impairs blood-brain barrier in ageing and disease.
Nature. 639:985–994. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Ding J, Lee SJ, Vlahos L, Yuki K, Rada CC,
van Unen V, Vuppalapaty M, Chen H, Sura A, McCormick AK, et al:
Therapeutic blood-brain barrier modulation and stroke treatment by
a bioengineered FZD4-selective WNT surrogate in mice.
Nat Commun. 14:29472023. View Article : Google Scholar
|
|
166
|
Sakamoto K, Iwata S, Jin Z, Chen L,
Miyaoka T, Yamada M, Katahira K, Yokoyama R, Ono A, Asano S, et al:
Cyclic peptides KS-133 and KS-487 multifunctionalized nanoparticles
enable efficient brain targeting for treating schizophrenia. JACS
Au. 4:2811–2817. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Pacchioni AM, Gabriele A, Donovan JL,
DeVane CL and See RE: P-glycoprotein inhibition potentiates the
behavioural and neurochemical actions of risperidone in rats. Int J
Neuropsychopharmacol. 13:1067–1077. 2010. View Article : Google Scholar
|
|
168
|
Brzozowska NI, de Tonnerre EJ, Li KM, Wang
XS, Boucher AA, Callaghan PD, Kuligowski M, Wong A and Arnold JC:
The differential binding of antipsychotic drugs to the ABC
transporter P-glycoprotein predicts cannabinoid-antipsychotic drug
interactions. Neuropsychopharmacology. 42:2222–2231. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Lin YC, Ellingrod VL, Bishop JR and Miller
DD: The relationship between P-glycoprotein (PGP) polymorphisms and
response to olanzapine treatment in schizophrenia. Ther Drug Monit.
28:668–672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Miyama T, Takanaga H, Matsuo H, Yamano K,
Yamamoto K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y and
Sawada Y: P-glycoprotein-mediated transport of itraconazole across
the blood-brain barrier. Antimicrob Agents Chemother. 42:1738–1744.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Qosa H, Miller DS, Pasinelli P and Trotti
D: Regulation of ABC efflux transporters at blood-brain barrier in
health and neurological disorders. Brain Res. 1628:298–316. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Al Shuhaimi L, Henman M, McCallion P,
McCarron M and O'Dwyer M: The adverse effects of long-term exposure
to anticholinergics among people with intellectual disabilities: A
scoping review. HRB Open Res. 5:632022. View Article : Google Scholar
|
|
173
|
Peng A, Chai J, Wu H, Bai B, Yang H, He W
and Zhao Y: New therapeutic targets and drugs for schizophrenia
beyond dopamine D2 receptor antagonists. Neuropsychiatr Dis Treat.
20:607–620. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Dhuria SV, Hanson LR and Frey WH II:
Intranasal delivery to the central nervous system: Mechanisms and
experimental considerations. J Pharm Sci. 99:1654–1673. 2010.
View Article : Google Scholar
|
|
175
|
Teleanu DM, Negut I, Grumezescu V,
Grumezescu AM and Teleanu RI: Nanomaterials for drug delivery to
the central nervous system. Nanomaterials (Basel). 9:3712019.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Harper SQ: Progress and challenges in RNA
interference therapy for Huntington disease. Arch Neurol.
66:933–938. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Loch-Neckel G, Matos AT, Vaz AR and Brites
D: Challenges in the development of drug delivery systems based on
small extracellular vesicles for therapy of brain diseases. Front
Pharmacol. 13:8397902022. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Alkhalifa AE, Al-Ghraiybah NF, Odum J,
Shunnarah JG, Austin N and Kaddoumi A: Blood-brain barrier
breakdown in Alzheimer's disease: Mechanisms and targeted
strategies. Int J Mol Sci. 24:162882023. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Moons T, de Roo M, Claes S and Dom G:
Relationship between P-glycoprotein and second-generation
antipsychotics. Pharmacogenomics. 12:1193–1211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Hardy RE, Chung I, Yu Y, Loh SHY, Morone
N, Soleilhavoup C, Travaglio M, Serreli R, Panman L, Cain K, et al:
The antipsychotic medications aripiprazole, brexpiprazole and
cariprazine are off-target respiratory chain complex I inhibitors.
Biol Direct. 18:432023. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Sykes DA, Moore H, Stott L, Holliday N,
Javitch JA, Lane JR and Charlton SJ: Extrapyramidal side effects of
antipsychotics are linked to their association kinetics at dopamine
D2 receptors. Nat Commun. 8:7632017. View Article : Google Scholar
|
|
182
|
Elschot EP, Backes WH, Postma AA, van
Oostenbrugge RJ, Staals J, Rouhl RPW and Jansen JFA: A
comprehensive view on MRI techniques for imaging blood-brain
barrier integrity. Invest Radiol. 56:10–19. 2021. View Article : Google Scholar
|
|
183
|
Tenchov R, Bird R, Curtze AE and Zhou Q:
Lipid nanoparticles-rom liposomes to mRNA vaccine delivery, a
landscape of research diversity and advancement. ACS Nano.
15:16982–17015. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Huntley MA, Bien-Ly N, Daneman R and Watts
RJ: Dissecting gene expression at the blood-brain barrier. Front
Neurosci. 8:3552014. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Futtrup J, Margolinsky R, Benros ME, Moos
T, Routhe LJ, Rungby J and Krogh J: Blood-brain barrier pathology
in patients with severe mental disorders: A systematic review and
meta-analysis of biomarkers in case-control studies. Brain Behav
Immun Health. 6:1001022020. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Xinchen Y, Jing T and Jiaoqiong G:
Lipid-based nanoparticles via nose-to-brain delivery: A mini
review. Front Cell Dev Biol. 11:12144502023. View Article : Google Scholar : PubMed/NCBI
|
